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Intradermal  injection of boiled yeast  cells (zymosan) or Bordetella  pertussis- 
killed organisms in the nonsensitized rabbit induces local inflammatory edema 
thought to be mediated by two endogenous substances acting synergistically (1). 
One mediator is a  vasodilator prostaglandin (PG); the other is a  substance that 
increases venular permeability to plasma proteins. This report is concerned with 
the second.  Incubation of blood plasma or lymph with zymosan (the standard 
inflammatory stimulus in these experiments) results in the generation of perme- 
ability-increasing activity. These plasma and lymph samples induce little edema 
when injected intradermally (measured by the 30-min accumulation of intrave- 
nously injected 125I-albumin) but are highly active mixed with vasodilator pros- 
taglandins (2). The permeability-increasing factor has been purified and charac- 
terized and its physico-chemical properties found to correspond to the comple- 
ment fragment C5a (3).  Although the chemical structure of rabbit  C5a is not 
established, the activity is stable in plasma in spite of the presence of carboxypep- 
tidase N, suggesting that rabbit C5a is active when devoid of its carboxyl terminal 
arginine (i.e., C5a des Arg).  Human C5a, with a  known structure (4), has also 
been shown to be a  potent permeability-increasing substance with and without 
its carboxyl terminal arginine (5). Again the presence of a vasodilator is required 
to induce significant edema formation in rabbit  skin.  Independence from the 
carboxyl  terminal arginine relates  permeability-increasing activity in rabbit  to 
leukotactic activity (6) rather than mast cell histamine release (7). Thus, it has 
been found that responses to C5a/prostaglandin  mixtures cannot be abolished 
by antihistamines (3), but are abolished by depletion of circulating polymorpho- 
nuclear  (PMN)  leukocytes  (5,  8).  This  indicates  that  increased  permeability 
induced by the presence of C5a in the extravascular tissue fluid results from a 
rapid interaction (within 6 min) between circulating PMN leukocytes and venular 
endothelial cells (8). 
From these observations it  is possible  to assemble the putative sequence of 
events  that  occurs  after  inflammatory  stimulus  and  leads  to  changes  in  the 
microvasculature characteristic of the acute inflammatory reaction (3, 5, 8). Until 
now, we have had no direct evidence of local extravascular generation of C5a in 
response  to  an  inflammatory  (e.g.,  microbial)  stimulus.  Therefore,  we  have 
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investigated  a  model  in  the  peritoneal  cavity  because  of the  relative  ease  in 
collection of exudate compared with the skin. Earlier, we reported the appear- 
ance  of permeability-increasing  activity,  prostaglandin,  plasma  proteins,  and 
PMN leukocytes in the rabbit peritoneal cavity in response to a local injection of 
zymosan (9). The permeability-increasing activity exhibited characteristics similar 
to those of C5a. Here we describe a radioimmunoassay (RIA) for rabbit C5a and 
the detection of high levels of immunoreactive C5a (irC5a) in peritoneal exudate 
in  response  to  zymosan.  Because  of the  relevance  of  these  observations  to 
inflammatory reactions initiated by antigen-antibody complexes, a reversed pas- 
sive Arthus-type reaction was also investigated in the peritoneal cavity, and again 
high levels of irC5a were detected. 
Materials and Methods 
Animals.  Male  New Zealand White rabbits (3.5-4 kg) were purchased from Buxted 
Farm, Sussex,  United Kingdom; and male Dunkin Hartley guinea pigs from David Hall, 
Darley Oakes Farm, Burton-on-Trent, Staffordshire, U.K. 
Materials.  Saffan (Alphaxolone and  Alphadoione) was  from  Glaxovet,  Greenford, 
Middlesex, U.K.; Evans blue dye from Searle Diagnostics,  High Wycombe, Buckingham- 
shire, U.K.; Arterioveine 11720,  14-gauge cannulae, from Vygon, 95440, Ecouen, France; 
Freund's complete and incomplete adjuvants (FCA, FIA) from Difco Laboratories, West 
Molesey, Surrey, U.K.; Na'25I from Amersham International, Amersham, Buckingham- 
shire,  U.K.; Enzymobeads from Bio-Rad Laboratories, Watford, Hertfordshire,  U.K.; 
Protein A Bacterial Adsorbent (PABA) from Miles Scientific, Stoke Poges, Slough, U.K.; 
carboxymethyi (CM)-Sephadex  C-25, Sephadex G-25M, Sephadex G-100, Polybuffer (PB 
96)  and  Polybuffer exchanger (PBE  94)  from Pharmacia  Fine Chemicals,  Hounslow, 
Middlesex, U.K.; CM-cellulose  CM32 from Whatman, Maidstone, Kent, U.K.; bovine 
gamma globulin (BGG)  from British Drug Houses, Poole,  Dorset,  U.K.  Zymosan was 
prepared by boiling bakers' yeast type II from Saccharomyces cerevisiae (Sigma Chemical 
Co.,  Poole,  Dorset,  U.K.) in  water followed by extensive washing and  lyophilization. 
Indomethacin was a  gift from Merck,  Sharp and  Dohme,  Hoddesdon, Hertfordshire, 
U.K. 
Collection of Inflammatory  Exudate from the Peritoneal Cavity.  Rabbits were anesthetized 
with Saffan (0.5  ml/kg) and given maintenance doses when required.  Evans  blue dye 
(2.5%  wt/vol,  0.5  ml/kg) was  injected i.v.  to enable plasma  protein  leakage into the 
peritoneal cavity to be monitored. A sterile 14-gauge  concentric polythene cannula and 
steel needle were inserted i.p. in each rabbit. The needle was withdrawn and 50 ml of a 
zymosan suspension in saline (10 mg/ml), or saline as a control, injected via the cannula. 
The cannula was stoppered, the abdomen gently massaged to disperse the injection fluid, 
ai,d a 3-ml sample withdrawn immediately by removing the stopper and collecting fluid 
intt; sodium EDTA pH 7.2 and indomethacin (10 mM and 5.6/zM final concentrations, 
respectively) on ice. After removal of 100/zl for a leukocyte count, the remainder was 
immediately centrifuged (7,800 g for 1 min) to ensure rapid separation of soluble factors 
from zymosan and leukocytes. Supernatants were stored at -20°C. This procedure was 
repeated at 1, 2, 4, and 6 h. The cannula was removed at 6 h and reinserted at 12 h for 
the final collection. Blood samples (1.5 ml, collected into EDTA and indomethacin) were 
taken from a small ear vein incision immediately before, and 1 h after, i.p. injection of 
zymosan. Blood samples were centrifuged at 7,800 g for 5 min and plasma samples stored 
at -20°C.  To collect exudate from reversed passive  Arthus-type reactions, the above 
procedure was used with the following differences. 50 ml of anti-BGG antiserum (diluted 
1/4) was injected i.p. followed 5 min later by an i.v. injection of BGG (5 mg/kg). Total 
available exudate was removed 2 h later. Antiserum was raised previously in rabbits by 
giving s.c.  injections (4  x  0.25  ml) of BGG (1  mg/ml emulsion) in FCA, followed by 
booster injections (4 x  0.25 ml) of the same BGG concentration in FIA at 14 d and an 
injection of alum-precipitated BGG (300  #g/0.1  ml) at  28  d.  Blood was collected by 
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for 30 min, and stored in aliquots at -20°C. An IgG fraction made from the antiserum 
by ammonium sulphate precipitation at 50% saturation and dialysis against saline was used 
in some experiments. 
Preparation of C5a.  Rabbit C5a (presumed to be CSa des Arg because of the action of 
serum  carboxypeptidase N)  w.as prepared  from  zymosan-activated serum  by step-wise 
elution from CM-Sephadex at pH 6.0 and gel filtration on Sephadex G-100 as described 
previously (3). This was followed by a second cation exchange step and chromatofocusing 
as described below. Sample was applied to a column (0.9 cm x  20 cm) of microgranular 
CM-ceilulose equilibrated in 0.1  M ammonium formate buffer, pH 5.0; the column was 
then  eluted  with a  linear gradient ending in  0.5  M ammonium formate, pH  5.0  (C5a 
eluted  at  0.3  M  buffer).  The chromatofocusing column  (0.9  cm  x  19  cm) contained 
Polybuffer exchanger 94 equilibrated in  0.025  M ethanolamine/HCI buffer, pH  10.5; 
sample was applied in Polybuffer 96 (adjusted to pH 7.0 with HC1) and eluted with the 
same buffer (C5a eluted at pH 9.0).  This preparation migrated as a single band (corre- 
sponding to 13,000 mol wt) in SDS-PAGE using an 8-20% acrylamide gradient gel. 
Preparation of Antiserum  to C5a.  Rabbit C5a  (640  #g/ml phosphate-buffered saline, 
PBS) was emulsified with an equal volume of FCA and 0.2 ml was injected into each of 
the rear foot pads of three guinea pigs (day 0).  A  similar emulsion was made with FIA 
and 0.5 ml injected subcutaneously in the neck on day 19. Each guinea pig received 6 x 
100  #1  intradermal  injections of C5a  (100  #g/ml  PBS) on days 26  and  34.  Blood was 
obtained by cardiac puncture on day 41  and the antiserum frozen in small aliquots.  A 
single precipitin band was obtained when this antiserum was reacted with C5a, zymosan- 
activated plasma or zymosan-induced peritoneal exudate fluid in double diffusion plates. 
125  125  Preparation of  I-C5a.  I-C5a (3-4 #Ci/#g protein) was prepared by incubation of 
rabbit C5a (10 #g) with  Na  1~5I (250 #Ci), -~glucose and solid phase glucose oxidase/ 
lactoperoxidase "Enzymobeads" in sodium phosphate buffer, pH 7.2.  The reaction was 
terminated after 45 min by adding sodium azide and centrifuging at 7,800 g for 1 min. 
The supernatant was mixed with carrier protein (bovine serum albumin, BSA) and sodium 
iodide and applied to a column (0.9  ×  16 cm) of Sephadex G-25M equilibrated in PBS 
containing BSA (2 mg/ml). Fractions containing iodinated protein were pooled and stored 
at 2 °C in the presence of sodium azide (0.1%). Using the RIA procedure described below; 
binding of radioactivity in the presence of excess antiserum was 85%. 
Radioimmunoassayfor C5a.  The buffer used for RIA was 0.1  M tricine-buffered saline, 
pH 8.0 containing 0.1% sodium azide (TBS). Protamine sulfate and gelatin were added 
where appropriate to ensure low nonspecific binding, as described (10) for RIA of human 
C5a.  Samples  (200  #1)  were  incubated  for  1 h  at  2°C  with  an  equal  volume of TBS 
containing polyethylene glycol 6000 (PEG, 22% wt/vol) and EDTA (10 raM) and centri- 
fuged for 5 min at 7,800 g in a microcentrifuge. Supernatants (300 #i) were removed and 
mixed with  TBS containing  7.5%  protamine sulfate (150  #1). PEG removes C5,  which 
cross-reacts with the anti-C5a serum, and IgG, which can interfere with the separation of 
free and antibody-bound tracer. The recovery of C5a from plasma was 84.8 +  1.0% (n = 
14),  from zymosan-induced peritoneal exudate  fluid  97.4  __.  0.6%  (n  =  18),  and  from 
saline-induced peritoneal exudate fluid 95.4 _+ 0.6% (n =  8). 
The concentrations  of reagents in  samples prepared as described above were:  PEG 
(7.3%), protamine sulfate (2.5%) and EDTA (6.7 mM); dilutions of sample and standard 
solutions of C5a were performed using TBS containing these reagents.  I-C5a, guinea 
pig anti-rabbit C5a and PABA (a solid phase reagent that binds IgG) were diluted in TBS 
containing protamine sulfate (2.5%) and gelatin (0.6%). Duplicate micro-centrifuge tubes 
containing  100 #1 volumes of sample or standard C5a were incubated for 16 h at room 
temperature (20-24°C) with  50 #1  125I-C5a (5  ng =  20,000  cpm) and  50 #l antiserum 
(diluted  1/5,000).  This was followed by a  30-rain  incubation  with  50 #1 of 2%  PABA. 
After dilution with 1 ml TBS (0.6% gelatin) and immediate centrifugation (2 min at 7,800 
g), supernatants were removed by suction and antibody-bound radioactivity in the pellets 
counted in an automatic gamma counter. 
Control binding in  the absence of added  C5a was 41.2  +  0.6%  (n  =  5),  nonspecific 
binding was 1.8 +  0.2% (n =  4) and the concentrations of C5a required to produce 10% 
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respectively. The limit of detection of the assay (assessed at 10% inhibition of binding and 
allowing for recovery and dilution of sample during preparation) was 24.0  ng/mi for 
plasma samples and 21.5 ng/ml for peritoneal exudate samples. The interassay coefficient 
of variation was 6.0% in five assays of the same sample. Results are given as the mean +_ 
SEM for n observations. Student's t test was used for statistical evaluation. 
Results 
Incubation (37°C  for  30  min) of rabbit  heparinized (10  U/ml) plasma  with 
different concentrations of zymosan resulted in the dose-related generation of 
irC5a as previously observed for the generation of permeability-increasing activ- 
ity (3). The highest dose of zymosan (10 mg/ml plasma) generated 5,820 +  590 
ng irC5a/ml (n  =  4  rabbits).  When zymosan-activated plasma was subjected to 
gel filtration on Sephadex  G-100,  a  single peak of irC5a was observed,  corre- 
sponding  with  the  peak  of permeability-increasing activity in  rabbit  skin  (3). 
Plasma prepared  from blood collected into sodium EDTA (10  mM) contained 
36.6  _+  2.3  ng  irCfa/ml  (n  =  4),  whereas  plasma  from  blood  collected  into 
heparin  (10  U/ml)  contained  53.5  _+  4.5  ng/ml (n  =  4) and serum  contained 
78.5 +  1.4 ng/ml (n =  3). For each rabbit, the values were always EDTA plasma 
<  heparinized plasma <  serum. We do not infer that we are detecting circulating 
C5a. These low levels may reflect slight activation during or after blood collec- 
tion, activation which may be increased by heparin or clotting (10). 
Fig.  1 shows the time course of generation of irC5a in rabbit peritoneal fluid. 
No irC5a was detected in fluid obtained after intraperitoneal injections of sterile 
saline (collection was terminated after 4 h  because little fluid was present in the 
cavity at this time).  In the rabbits  given intraperitoneal  injections of zymosan, 
irC5a concentrations rose from a  low level at 0 h to high levels at 1, 2, and 4 h, 
with a  maximum of 802 +  184 ng/ml at 2 h. By 6 h  the concentration was 302 
_+ 63 ng/ml, falling to a low level at 12 h. No significant differences in the levels 
of irC5a were found in blood plasma samples taken before (44.2 _+ 3.9 ng/ml, n 
=  5) and 1 h after (41.9 _+ 6.1 ng/ml, n =  4) intraperitoneal injection of zymosan. 
Peritoneal exudate  fluid recovered  2  h  after initiation of a  reversed passive 
Arthus-type reaction contained concentrations of 304 _+ 60 ng irC5a/ml (n =  6) 
using unfractionated antiserum and 330 +  30 ng irC5a/ml (n =  3) using the IgG 
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FIGURE  1.  Time course of appearance of immunoreactive C5a (irC5a) in exudate fluid 
generated in response to an i.p. injection of zymosan (0; 500 mg suspended in 50 ml saline) 
in the rabbit. Control samples were taken from rabbits given intraperitoneal saline (O). The 
ordinate represents the irC5a level measured by RIA and the abscissa the time of collection 
following  intraperitoneal injection. The values  are given as mean _+ SEM for n = 4 rabbits. 
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fraction. The mean total recovery per animal in these 9 experiments was 10,300 
_+ 2,300 ng irC5a. 
Discussion 
Our  previous  studies  suggest  that  certain  inflammatory  stimuli,  e.g.  some 
microbial cell walls, can initiate a nonallergic local edema response in rabbit skin 
that is dependent on extravascular complement activation (3).  C5a is liberated 
as a byproduct of activation and this peptide causes circulating PMN leukocytes 
to attach to venular endothelial cells, followed by leukocyte emigration into the 
tissue.  This cell-cell  interaction,  by an  unknown mechanism, induces a  rapid 
increase in venular permeability resulting in leakage of blood proteins leading 
to tissue edema (8).  Protein leakage has been interpreted as functional in this 
response, as blood proteins will be supplied to the tissue in proportion to the size 
of the stimulus (3, 5, 8). Thus, C5a controls the supply of complement compo- 
nents in order to effect extravascular microbial lysis and opsonization, and also 
controls the accumulation of phagocytic leukocytes. 
The rate of leakage of plasma proteins from venules is dependent on blood 
supply. In rabbit skin, with its low basal blood flow, the concomitant generation 
of a vasodilator prostaglandin is necessary for significant leakage to occur (3). In 
the  peritoneal  cavity,  with  higher  basal  blood  flow,  prostaglandins  would be 
expected to enhance leakage without being obligatory. We have found that the 
vasodilator PGI~ (prostacyclin) is released in the cavity in response to zymosan as 
evidenced by the high levels of its inactive metabolite 6-oxo-PGF~ in exudate 
(9).  In the same study it was shown that the exudate was able to induce edema 
in the skin when mixed with a  stable vasodilator,  PGE~, and injected intrader- 
mally.  In this paper we describe a  radioimmunoassay for rabbit  C5a  and the 
demonstration  of  high  levels  of  irC5a  in  peritoneal  inflammatory  exudates 
induced by zymosan and in an Arthus-type reaction. The levels detected (i.e., up 
to 80 ng/100/~1) are well above the minimum effective dose for responses in skin 
(i.e., less than 10 ng]100 ~1 in the presence of PGE2) (8). 
Ward and Hill (11) found that extracts of Arthus lesions in rat skin contained, 
in addition to chemotactic activity, a C5 cleaving enzyme activity thought to be 
derived from  PMN  leukocytes.  Depletion of circulating PMN  leukocytes was 
found to suppress the level of C5-related chemotactic activity in Arthus lesions 
(11) and it has been postulated that >90% of the activity present in such lesions 
is derived from C5 by the action of leukocyte-derived enzymes, rather than from 
complement activation (12). The results presented here do not illuminate on this 
interesting hypothesis because the RIA will not distinguish between these two 
sources of C5a generation.  Further, the antiserum used is likely to cross-react 
with heterogeneous C5 fragments, containing all or part of the C5a sequence, 
generated  by  leukocyte-derived  enzymes.  However,  our  findings  lead  us  to 
suggest an alternative explanation for the observations of Ward and Hill (11). 
PMN leukocytes, in their interaction with the vessel wall, are effectively regulat- 
ing the supply of complement components, including C5, to the tissue. There- 
fore, depletion of PMN leukocytes would be expected to reduce the extent of 
extravascular  complement activation  and  consequently the  level of C5a.  The 
protease inhibitor Trasylol, which inhibits the cleavage of C5 by PMN leukocyte- 
derived enzymes in vitro (13),  does not inhibit the generation of C5a  during 
complement activation  nor  the  production of edema induced by  zymosan  in 2182  JOSE ET  AL.  BRIEF  DEFINITIVE REPORT 
rabbit skin (3).  This suggests that complement activation is more important in 
this model than cleavage of C5 by leukocyte-derived enzymes. It will be interest- 
ing to determine which of the mechanisms for generating C5-related chemotactic 
activity predominate in different inflammatory reactions. 
Summary 
We describe a radioimmunoassay for rabbit C5a and its use to obtain evidence 
of extravascular C5a generation in two inflammatory reactions in the peritoneal 
cavity. These observations, together with the potent activity of C5a in inducing 
increased  microvascular  permeability  involving  circulating  PMN  leukocytes, 
strengthen the case for considering C5a an important inflammatory mediator. 
These findings offer an explanation for the many different experimental inflam- 
matory reactions where oedema formation can be suppressed either by systemic 
depletion of complement or by depletion of circulating PMN ieukocytes. 
Received for publication  13 September 1983. 
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